BioequivalencePhase 1NCT04882826
Bioequivalence Study of Two Formulations of Sildenafil Tablet 100 mg in Healthy Male Volunteers Under Fasting Conditions
A Phase 1 study testing Sildenafil film-coated tablet 100 mg and Viagra® film-coated tablet 100 mg in people with Bioequivalence, run by Pharmtechnology LLC at 1 site in Russia.
Trial summary
This is an open-labeled (laboratory blinded), randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Viagra®, 100 mg film-coated tablets) or the test (Sildenafil, 100 mg film-coated tablets) formulation in each period of study (sequences… Read more about this study
- Who is it for?
- Ages 18 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Bioequivalence
- What is being tested?
- Sildenafil film-coated tablet 100 mg and Viagra® film-coated tablet 100 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 44 participants
- Where
- 1 siteRussia
- Study dates
- 10 May 2021to 30 May 2021
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy caucasian men aged between 18 to 45 years
- The written consent of the volunteer to be included in the study
- Verified diagnosis "healthy" according to the anamnesis data and the results of standard clinical, laboratory and instrumental examination methods, physical examination and anamnestic examination
- Body mass index 18.5-30 kg/m² according to Quetelet's weight-height index
- The results of an X-ray or fluorographic examination of the chest organs within the normal range (the results of an examination carried out within 12 months before the start of the study may be provided)
- Absence of ophthalmological disease according to the data of the ophthalmological examination
- Consent to use a double barrier method of contraception (condom + spermicide) or sexual continence, as well as consent not to take part in sperm donation from the moment of taking the drug in the first period, during the entire study and within 14 days after taking the drug in the second period research
- Subjects are able to understand the requirements of the study, to sign a written informed consent, and also to accept all the restrictions imposed during the course of the study, and to agree to return for the required investigations
Who cannot join
- Burdened allergic history, hypersensitivity to sildenafil or excipients that are part of any of the investigational drugs, or intolerance to these components.
- Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
- Anatomical deformation of penis (angulation, cavernous fibrosis, or Peyronie's disease).
- History of priapism.
- Hereditary retinitis pigmentosa.
- Episodes of development of anterior non-arteritis ischemic neuropathy of the optic nerve.
Show all 36Show fewer
- Organic brain damage, a history of increased convulsive readiness.
- Acute or chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, and also diseases of the gastrointestinal tract, liver, kidneys and blood, eye disease.
- Other diseases that, in the opinion of the researcher, may affect the absorption, distribution, metabolism or excretion of both drugs, or increase the risk of negative consequences for the volunteer.
- The presence of mental disorders, including a history.
- Surgical interventions on the gastrointestinal tract, with the exception of appendectomy.
- Acute infectious diseases that ended less than 4 weeks before taking the drug in the first period.
- Dehydration due to diarrhea, vomiting or other reason within the last 24 hours before taking the drug in the first period of the study, if vomiting or diarrhea wasn't a manifestation of an infectious disease.
- Clinically significant abnormalities on the ECG, the level of systolic blood pressure (SBP) measured in the sitting position at the time of screening <100 mm Hg or ≥ 130 mm Hg and / or diastolic blood pressure (DBP) <60 mm Hg or ≥ 85 mm Hg.
- Heart rate less than 60 beats/min or more than 90 beats/min at the time of screening, respiratory rate less than 14 or more than 18 per minute at the time of screening, body temperature below 36.0 ° C or above 37.0 °C at the time of screening.
- Use of any prescription and OTC drugs including herbs and food additives, vitamins that can have a significant effect on the PK of sildenafil or data on the effect of which on the pharmacokinetics of sildenafil are unknown, as well as question the characterization of the volunteer as healthy, less than 14 days before taking the drug in the first period;
- Use of well-known inhibitors or inducers of liver microsomal enzymes (barbiturates, omeprazole, cimetidine, etc.) or antiviral drugs less than 2 months before enrollment in the study.
- The use of donors of nitric oxide, organic nitrates or nitrites in any form less than 30 days before taking of the drug in the first period.
- Donation of plasma or blood (450 ml or more) less than 2 months (60 days) before taking the drug in the first period.
- Consumption of caffeine and xanthine-containing drinks and products (tea, coffee, chocolate, cola, etc.), products containing poppy seeds, less than 48 hours before taking the drug in the first period.
- Consumption of alcohol and alcohol-containing foods and beverages less than 48 hours before taking the drug in the first period.
- Use of citrus fruits (including grapefruit and grapefruit juice) and cranberries (including juices, fruit drinks, etc.) less than 7 days before taking the drug in the first period.
- Intake of more than 10 units alcohol per week (1 unit of alcohol is equivalent to 500 ml of beer, 200 ml of dry wine or 50 ml of spirits) or history of alcoholism, drug addiction, drug abuse.
- Intense physical activity less than 24 hours before taking the drug in the first period.
- Smoking more than 10 cigarettes less than 24 hours before taking the drug in the first period.
- Participation in other clinical trials of drugs less than 3 months before taking the drug in the first period.
- Following any low sodium diet within 2 weeks prior to study initiation, or following a special diet (vegetarian, vegan, with limited salt intake) or lifestyle (night work, extreme physical activity).
- Test positive for syphilis, hepatitis B, hepatitis C or HIV at the time of screening.
- Positive test for alcohol in exhaled air at screening.
- Positive urinalysis for the content of narcotic and potent substances during screening (opiates, morphine, barbiturates, benzodiazepines, cannabinoids/marijuana).
- The value of standard laboratory and instrumental parameters that go beyond the reference values.
- Lack of intention of volunteers to comply with the Protocol requirements throughout the course of the study and/or lack, in the opinion of the Investigator, of the volunteers' ability to understand and evaluate the information on this study as part of the informed consent form signing process, in particular regarding the expected risks and possible discomfort.
- Mental, physical and other reasons that do not allow the volunteer to adequately assess their behavior and correctly comply with the conditions of the research protocol.
- Tattooing and piercing within 30 days prior to first drug administration.
- Difficulty swallowing tablets.
- Difficulty with taking blood (for example, difficult access to the veins).
Trial locations and contacts
1 site in 1 country.
Andrei Yaremchuk contact
Russia1 site
Private healthcare institution "Clinical Hospital "RZD-Medicine" of the city of Yaroslavl"
Yaroslavl, 150047
About this study
Official title: Randomized Crossover 2 Period Single Dose Bioequivalence Study of 2 Formulations Sildenafil Tablets 100mg (Pharmtechnology LLC, Belarus) and Viagra® Tablets 100mg (Fareva Amboise, France) in Healthy Male Volunteers Under Fasting Conditions
This is an open-labeled (laboratory blinded), randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Viagra®, 100 mg film-coated tablets) or the test (Sildenafil, 100 mg film-coated tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent
- Conditions
- Bioequivalence
- Being tested
- Sildenafil film-coated tablet 100 mg, Viagra® film-coated tablet 100 mg
- Keywords
- Sildenafil, Bioequivalence, Viagra
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sildenafil film-coated tablet 100 mgDrug
Also called The test product
Sildenafil is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 100 mg of sildenafil.
Viagra® film-coated tablet 100 mgDrug
Also called The reference product
Viagra® is manufactured by Fareva Amboise, France. Each tablet contains 100 mg of sildenafil.
| Study group | Role | What they receive |
|---|---|---|
| Sequence TR | Other | 22 subjects assigned to the sequence TR will receive a single 100 mg dose of the test product Sildenafil (1 x 100 mg tablet), marked as T in the sequence, in Period 1 and a single 100 mg dose of the reference product Viagra® (1 x 100 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken. Receives: Drug: Sildenafil film-coated tablet 100 mg; Drug: Viagra® film-coated tablet 100 mg |
| Sequence RT | Other | 22 subjects assigned to the sequence RT will receive a single 100 mg dose of the reference product Viagra® (1 x 100 mg tablet), marked as R in the sequence, in Period 1 and a single 100 mg dose of the test product Sildenafil (1 x 100 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken. Receives: Drug: Sildenafil film-coated tablet 100 mg; Drug: Viagra® film-coated tablet 100 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cmax of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.
Maximum observed concentration in plasma.
Measured: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
AUC0-t of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference.
Cumulative area under the concentration time curve calculated from 0 to time of last observed quantifiable concentration (TLQC) using the linear trapezoidal method
Measured: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
Secondary outcomes (8)
Tmax of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.
Time of maximum observed concentration; if it occurs at more than one time point, Tmax is defined as the first time point with this value.
Measured: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
TLQC of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.
Time of last observed quantifiable concentration.
Measured: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
AUC0-INF of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.
Area under the concentration time curve extrapolated to infinity, calculated as AUC0-t + ĈLQC (the predicted concentration at time TLQC) / λZ (apparent elimination rate constant).
Measured: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
Residual area of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.
Extrapolated area (i.e. percentage of AUC0-INF due to extrapolation from TLQC to infinity).
Measured: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
Time point where the log-linear elimination phase begins (TLIN) of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference. products.
Time point where the log-linear elimination phase begins.
Measured: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
λZ of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.
Apparent elimination rate constant, estimated by linear regression of the terminal linear portion of the log concentration versus time curve.
Measured: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
Terminal elimination half-life (Thalf) of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.
Terminal elimination half-life, calculated as ln(2)/λZ.
Measured: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
Number of treatment-emergent adverse events for the test and the reference products.
The safety population will include all subjects who received at least one dose of the test or the reference product. Any significant changes will be recorded as treatment-emergent adverse events only if they are judged clinically significant by the qualified investigator or delegate.
Measured: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 May 2021
- Study start10 May 2021 (estimated)
- Primary completion30 May 2021 (estimated)
- Study completion30 May 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BioequivalenceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 44 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Pharmtechnology LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- ClinPharmInvest, LLC
- Responsible party
- Sponsor
- Investigators
- Alexander Khokhlov, Principal investigator, ClinPharmInvest, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04882826
- Sponsor's protocol ID
- SLDF-2020-CPI-FRMT
- Status last verified
- May 2021
- First submitted
- 6 May 2021
- Last updated
- 12 May 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Crossover 2 Period Single Dose Bioequivalence Study of 2 Formulations Sildenafil Tablets 100mg (Pharmtechnology LLC, Belarus) and Viagra® Tablets 100mg (Fareva Amboise, France) in Healthy Male Volunteers Under Fasting Conditions
- ClinicalTrials.gov ID
- NCT04882826
- Acronym / sponsor ID
- SLDF-2020-CPI-FRMT
- Conditions
- Bioequivalence
- Keywords
- Sildenafil, Bioequivalence, Viagra
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 44 participants (estimated)
- Lead sponsor
- Pharmtechnology LLCIndustry (pharma, biotech, devices)
- Collaborators
- ClinPharmInvest, LLC
- Study start
- 10 May 2021 (estimated)
- Primary completion
- 30 May 2021 (estimated)
- Study completion
- 30 May 2021 (estimated)
- First posted
- 12 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an open-labeled (laboratory blinded), randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Viagra®, 100 mg film-coated tablets) or the test (Sildenafil, 100 mg film-coated tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sequence TR | Other | Drug: Sildenafil film-coated tablet 100 mg, Drug: Viagra® film-coated tablet 100 mg22 subjects assigned to the sequence TR will receive a single 100 mg dose of the test product Sildenafil (1 x 100 mg tablet), marked as T in the sequence, in Period 1 and a single 100 mg dose of the reference product Viagra® (1 x 100 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken. |
| Sequence RT | Other | Drug: Sildenafil film-coated tablet 100 mg, Drug: Viagra® film-coated tablet 100 mg22 subjects assigned to the sequence RT will receive a single 100 mg dose of the reference product Viagra® (1 x 100 mg tablet), marked as R in the sequence, in Period 1 and a single 100 mg dose of the test product Sildenafil (1 x 100 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Healthy caucasian men aged between 18 to 45 years
- The written consent of the volunteer to be included in the study
- Verified diagnosis "healthy" according to the anamnesis data and the results of standard clinical, laboratory and instrumental examination methods, physical examination and anamnestic examination
- Body mass index 18.5-30 kg/m² according to Quetelet's weight-height index
- The results of an X-ray or fluorographic examination of the chest organs within the normal range (the results of an examination carried out within 12 months before the start of the study may be provided)
Key exclusion criteria (36 listed)
- Burdened allergic history, hypersensitivity to sildenafil or excipients that are part of any of the investigational drugs, or intolerance to these components.
- Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
- Anatomical deformation of penis (angulation, cavernous fibrosis, or Peyronie's disease).
- History of priapism.
- Hereditary retinitis pigmentosa.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sildenafil film-coated tablet 100 mgAlso: The test productSildenafil is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 100 mg of sildenafil. | Drug | Sequence RT, Sequence TR |
| Viagra® film-coated tablet 100 mgAlso: The reference productViagra® is manufactured by Fareva Amboise, France. Each tablet contains 100 mg of sildenafil. | Drug | Sequence RT, Sequence TR |
Primary outcome
Cmax of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.
Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
Maximum observed concentration in plasma.
AUC0-t of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference.
Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
Cumulative area under the concentration time curve calculated from 0 to time of last observed quantifiable concentration (TLQC) using the linear trapezoidal method
8 secondary outcomes
Tmax of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.
Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
TLQC of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.
Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
AUC0-INF of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.
Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
Residual area of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.
Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
Time point where the log-linear elimination phase begins (TLIN) of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference. products.
Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
λZ of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.
Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
Terminal elimination half-life (Thalf) of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.
Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
Number of treatment-emergent adverse events for the test and the reference products.
Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2021.
Related trials for Bioequivalence
Not yet recruitingPhase 1
A Study of Imlunestrant (LY3484356) in Healthy Female Participants
Healthy
RecruitingPhase 1
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects
Cetuximab, Bioequivalence
RecruitingPhase 1
Bioequivalence Study Between YHP2508B and YHR2602 in Healthy Subjects
Healthy Subjects (HS)
Active, not recruitingPhase 1
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Prostatic Neoplasms
RecruitingPhase 1
Bioequivalence Study Between YHP2508A and YHR2601 in Healthy Subjects
Healthy Subjects (HS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andrei Yaremchuk contact
Alexander Khokhlov principal investigator
ClinPharmInvest, LLC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Sildenafil film-coated tablet 100 mg and Viagra® film-coated tablet 100 mg in people with Bioequivalence, run by Pharmtechnology LLC at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 36 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 12 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Veronika Kumpel (80173094418, specialist.fs@ft.by), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cmax of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products. (time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2021.